Intellipharmaceutics International Inc. Stock Analysis IPCI.H.V

Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario and currently employs 11 full-time employees. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. The company has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The firm has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.